Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec vs insulin glargine 300 units/mL in type 2 diabetes mellitus inadequately controlled on basal insulin
2016-002801-20Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Insulin degludec once daily with Insulin glargine 300 units/mL once daily (2 arms). Primary endpoint: Number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes. Started Dec 2016; status: completed.
02
Drugs
insulin degludecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-002801-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002801-20.